ID
30369
Beskrivning
https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609
Länk
https://clinicaltrials.gov/ct2/show/NCT00486954
Nyckelord
Versioner (1)
- 2018-05-30 2018-05-30 - Halim Ugurlu
Rättsinnehavare
GlaxoSmithKline (GSK)
Uppladdad den
30 maj 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Blood Products and Blood Supportive Care Products, Paclitaxel Premedications
Similar models
Blood Products and Blood Supportive Care Products, Paclitaxel Premedications
C0371802 (UMLS CUI [1,2])
C1521826 (UMLS CUI [1,2])
C1519795 (UMLS CUI [1,2])
C0033045 (UMLS CUI-2)
C1519795 (UMLS CUI [1,2])